Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy. He also details their commitment to global operational excellence and a culture of employee purpose.
SK pharmteco’s Three-Business-Unit Strategy: Small Molecules, Peptides, and Viral Vectors
